The Scorch Protocol: T2 for Metabolic Research (Complete Breakdown)
Among T2-focused research frameworks circulating in the metabolic-research community, the Scorch Protocol is the most widely discussed. Where most thyroid-adjacent research conversations center on T3 - its nuclear receptor activity, its role in Wilson's Protocol, its conversion from T4 - the Scorch Protocol takes a different angle entirely. It positions 3,5-T2 (3,5-diiodothyronine) as the primary active agent in a framework oriented around lipid metabolism, non-stimulant metabolic acceleration, and the specific mitochondrial pathway that separates T2 from every other tool in the thyroid hormone family.
The framework is described on scorchprotocol.com and has been discussed extensively across metabolic-research forums, biohacking communities, and thyroid-optimization groups over the past several years. The level of forum engagement reflects something real: T2's mechanism genuinely differs from the stimulant-class and receptor-mediated tools that most metabolic-research protocols rely on, and the Scorch framing - which foregrounds the mitochondrial lipid-oxidation mechanism and the TSH-safety argument - has resonated with researchers looking for a non-stimulant option with a favorable safety profile. This post provides the complete breakdown of what the protocol is, how its proposed dose ranges are discussed in research-forum contexts, what the underlying science supports, and where the framework fits relative to other T2 research approaches.
Research Grade · Discreet Worldwide Shipping
SRT3+T2-15 Slow Release T3+T2
Research framing. This article reviews the Scorch Protocol and 3,5-T2 from a research-context standpoint. All compounds discussed are sold strictly for laboratory research and not for human consumption. See our /faq#legality page for full terms.
What Is the Scorch Protocol?
The Scorch Protocol is a T2-centric metabolic-research framework centered on lipid metabolism and non-stimulant metabolic acceleration via 3,5-diiodothyronine. Unlike the Wilson's Protocol family, which is primarily aimed at correcting T4-to-T3 conversion dysfunction in hypothyroid-adjacent populations, the Scorch Protocol is positioned as a metabolic-rate tool - a framework for researchers investigating fat oxidation, thermogenesis, and mitochondrial energy output through the specific lens of T2 monotherapy.
The origin of the framework is the research community rather than the published clinical literature. There is no peer-reviewed publication defining "the Scorch Protocol" as a formal regimen. What exists is a community-developed framework built on the T2 biochemistry literature - primarily the cytochrome c oxidase binding data from Goglia and Lanni, the hepatic fatty acid oxidation findings, and the TSH-suppression comparative data - assembled into a practical research-application structure with defined dose ranges, cycling recommendations, and monitoring guidance.
The three claims most consistently circulated in the Scorch Protocol community are:
- T2 hits mitochondria directly via cytochrome c oxidase binding, bypassing the hours-long genomic cascade that T3 requires.
- At typical research doses (under 300 mcg/day), T2 does not suppress TSH the way T3 does - meaning researchers can pursue metabolic acceleration without the HPT-axis load that T3 protocols carry.
- T2-driven metabolic rate elevation spares muscle tissue in the way that high-dose T3 protocols do not, because T2's weak nuclear receptor affinity means it does not activate the genomic cascades responsible for T3-associated muscle catabolism.
These three claims each have meaningful support in the animal-model and biochemistry literature. The degree to which they translate to human research subjects in the specific protocol design the Scorch framework proposes is a question the literature answers only partially - which the section on established vs. unestablished findings addresses directly.
For background on T2's fundamental mechanism and isomer identity, see the 3,5-T2 complete guide.
The Core Premise: T2 as a Non-Stimulant Metabolic Tool
The Scorch Protocol's central positioning - and the reason it has attracted a research community distinct from the T3 world - is its framing of T2 as a metabolic accelerator that works without nervous system stimulation.
Most tools used in metabolic-rate and fat-oxidation research work through the central nervous system. Caffeine inhibits phosphodiesterase and blocks adenosine receptors, producing increased cyclic AMP and sympathetic tone. Yohimbine blocks alpha-2 adrenergic receptors, increasing noradrenaline release. Ephedrine-class compounds directly stimulate adrenergic receptors. Even the selective beta-3 adrenergic agonists investigated in obesity research work through sympathomimetic pathways. The metabolic acceleration these compounds produce is inseparable from CNS stimulation - elevated heart rate, blood pressure changes, anxiety, sleep disruption, and tolerance development are characteristic features of the entire class.
T2's mechanism of action operates entirely outside this pathway. As established by Goglia and colleagues in the 1994 FEBS Letters study, 3,5-T2 binds directly to subunit Va of cytochrome c oxidase - the terminal enzyme of the mitochondrial electron transport chain, Complex IV - and elevates the rate of aerobic respiration through direct enzymatic activation. No adrenergic signaling is involved. No cyclic AMP cascade. No nervous system stimulation of any kind. The metabolic rate elevation that results is a direct consequence of increased electron transport chain throughput at the mitochondrial level.
This is the Scorch Protocol's central selling point in research-community discussion: a tool that raises metabolic rate through the mitochondrial pathway without the stimulant profile that limits CNS-active compounds in sensitive research populations. Researchers who have experienced adverse effects from stimulant-class metabolic tools - cardiovascular sensitivity, anxiety, insomnia - find T2's mechanism appealing precisely because the physiological pathway is different at the root level.
The comparison to T3 is also relevant here. T3 does elevate metabolic rate, but it does so primarily through the genomic pathway - nuclear receptor activation, gene transcription, protein synthesis - which takes hours to days to produce measurable effects and carries significant HPT-axis suppression at doses required for meaningful metabolic acceleration. T2's acute cytochrome c oxidase activation produces metabolic rate elevation that is both faster and mechanistically distinct from T3's genomic route. For a complete side-by-side of all three thyroid hormones across mechanism, receptor affinity, half-life, and TSH suppression, see the T2 vs T3 vs T4 comparison.
T2 Dose Ranges in the Scorch Protocol
Research-forum discussions of the Scorch Protocol converge on a set of dose ranges that reflect the T2 research literature while remaining within the range that community tracking has associated with a favorable TSH safety profile.
View Scorch Protocol dose ranges discussed in research forums
| Phase | Reported T2 dose | Schedule |
|---|---|---|
| Starting | 50-100 mcg/day | Once daily, morning |
| Standard | 100-200 mcg/day | 1-2 doses |
| Higher-range research | 200-300 mcg/day | 2-3 split doses |
Important: doses above 300 mcg/day are where TSH suppression risk begins to enter the picture per animal-model extrapolation. Research-community discussions generally stay at or below 300 mcg/day.
The research-community rationale for starting at the lower end of this range is consistent with the broader T2 literature. At 50-100 mcg/day, cytochrome c oxidase stimulation is present and measurable in animal-model extrapolation, while the systemic load is low enough to allow researchers to assess individual response before escalating. The standard 100-200 mcg/day range represents the core of Scorch Protocol community discussion - this is the dose range where the hepatic lipid oxidation and resting metabolic rate elevation effects from the Lanni et al. research are most directly applicable in scale-extrapolation.
The SRT3+T2-15 entry-strength capsule, containing 15 mcg T3 and 15 mcg T2 in sustained-release form, is the closest research-catalog reference for the lower end of Scorch Protocol T2 dosing paired with T3 co-supplementation. For researchers working at the T2-monotherapy level, the T2 dose discussion in the Scorch framework sits above this entry level - but the entry product represents the starting point for researchers approaching T2 research from the combined T3+T2 direction.
Cycling vs Continuous: How the Protocol Is Run
The Scorch Protocol community discussion divides on the question of cycling versus continuous dosing. Both approaches are represented in research-forum contexts, with different rationales advanced for each.
View Scorch Protocol cycling approaches discussed in research forums
Cyclic approach (most commonly discussed): 4-6 week on-periods followed by 2-4 week off-periods. The rationale is that cycling preserves receptor and enzyme sensitivity, prevents potential downregulation of the cytochrome c oxidase pathway, and allows researchers to observe whether metabolic benefits persist into the off-period - which would suggest that the protocol is producing durable metabolic changes rather than purely acute effects that disappear on discontinuation.
Continuous lower-dose approach: Some research-forum discussions favor a sustained lower-dose strategy - 100 mcg/day or below - run continuously rather than in defined cycles. The argument here is that T2's short half-life (measured in hours, considerably shorter than T3's ~24-hour half-life) means the compound clears rapidly, limiting accumulation, and that at sub-100 mcg doses the HPT-axis concern is minimal enough that cycling is not mechanistically necessary.
Practical consideration: The cycling discussion in the Scorch community partly reflects the general research-protocol principle that compounds acting on receptor or enzyme pathways benefit from periodic washout periods to maintain response. Given that T2's direct mechanism involves cytochrome c oxidase rather than a receptor that can be classically downregulated, the cycling rationale is less mechanistically clear-cut than it is for receptor-active compounds. The community discussion remains unresolved on this point.
Neither cycling approach has been tested in controlled human studies. The 4-6 week on / 2-4 week off structure mirrors the general cycling conventions used across the research community for thyroid-adjacent and metabolic compounds, and it is the more frequently cited framework in Scorch Protocol community discussion.
Lipid-Cleansing Mechanism
The "lipid-cleansing" framing that appears in Scorch Protocol discussion is grounded in a body of animal-model research, primarily the work of Lanni, Moreno, Goglia, and colleagues published over the past two decades. The central finding is that 3,5-T2 administration in rodent models produces measurable acceleration of fatty acid oxidation in the liver, accompanied by reductions in stored hepatic triglycerides, serum triglycerides, and serum free fatty acid concentrations.
The mechanistic link is direct. T2 binds cytochrome c oxidase and elevates Complex IV activity, increasing the electron transport chain's capacity to process reducing equivalents (NADH and FADH2). Increased ETC throughput creates increased demand for the beta-oxidation of fatty acids - the metabolic process that converts long-chain fatty acids into the acetyl-CoA, NADH, and FADH2 that feed the ETC. The liver, which is the primary site of T2 action in most of this research (reflecting hepatic expression of DIO1 and the high T2 metabolic activity of liver mitochondria), responds by upregulating fatty acid uptake and oxidation to meet the increased ETC demand.
The Lanni et al. 2009 paper (PMID 19324040) is the core reference for this mechanism. It documents T2-induced increases in hepatic mitochondrial fatty acid oxidation rates in rat models and includes measurements of reduced hepatic triglyceride accumulation alongside the elevated oxidation rates. The findings are replicable and consistent across multiple publications from the same research group and independent groups.
The "lipid-cleansing" terminology is community framing, not the language used in the academic literature. The peer-reviewed description is more precise: accelerated hepatic fatty acid oxidation, reduced hepatic steatosis markers, and lowered serum lipid fractions in the rodent models. Whether those findings translate directly to the specific lipid-profile outcomes that Scorch Protocol community discussion implies in human research subjects is a question the human clinical data have not yet fully answered.
The critical advantage highlighted in Scorch Protocol discussion - and supported by the rodent-model comparisons - is that T2 achieves these lipid-metabolism effects without the muscle-wasting profile associated with high-dose T3. T3's nuclear receptor-mediated genomic signaling at suprathysiological doses activates ubiquitin-proteasome pathway genes in skeletal muscle, producing accelerated muscle protein catabolism. T2's weak nuclear receptor affinity means it does not drive those genomic cascades. The fatty acid oxidation acceleration proceeds through the mitochondrial pathway while the genomic muscle-catabolism signal remains quiet. This distinction is one of the reasons the Scorch Protocol frames T2 as specifically suited to body-composition research applications.
Why Scorch Protocol Doesn't Disrupt TSH at Typical Doses
The TSH safety argument is central to the Scorch Protocol's appeal, and it is the claim most directly supported by the peer-reviewed literature.
The animal-model evidence on this point is clear. In comparative studies examining the potency of T2 versus T3 for TSH suppression, 3,5-T2 has been shown to have approximately 10 times lower potency than T3 at equivalent doses. The paper most directly relevant to the Scorch Protocol community discussion is the 2008 study by Rivas et al. (PMID 19033545), which examined TSH suppression potency of 3,5-T2 versus T3 in rodent models and confirmed the substantially lower HPT-axis impact of T2.
The mechanistic reason for this difference is the receptor affinity data. TSH suppression is mediated primarily through TRbeta in the pituitary - the nuclear receptor isoform responsible for negative feedback on TSH secretion. T3 binds TRbeta with high affinity, producing strong pituitary feedback and rapid TSH suppression with even modest dose escalation. T2's binding affinity for TRbeta is approximately 10-60 times lower than T3's (data from PMID 16219922), which translates directly to the ~10 times lower TSH suppression potency observed in whole-animal studies. The pituitary receptor simply does not respond to T2 with the same suppressive feedback it delivers to T3.
The practical consequence for Scorch Protocol research subjects is that the dose range where cytochrome c oxidase stimulation and fatty acid oxidation effects are present - roughly 100-200 mcg/day - is well below the dose range at which consumer tracking and research-forum reporting suggests meaningful TSH disruption begins. Research-community reports consistently place oral T2 doses below approximately 300 mcg/day in the range where primary TSH suppression is not a consistent finding, which aligns with the animal-model extrapolation from the ~10x lower potency data.
This TSH safety argument distinguishes Scorch Protocol T2-monotherapy research from T3 protocols in a practically important way. A researcher pursuing metabolic rate acceleration with T3 faces a direct tradeoff between metabolic effect and HPT-axis suppression: more T3 means more metabolic effect and more TSH suppression, and the two cannot be separated. T2's weak TRbeta affinity means that metabolic rate acceleration via cytochrome c oxidase activation can proceed at doses that produce minimal HPT-axis feedback. The mitochondrial and genomic signaling pathways are decoupled in a way that T3 monotherapy cannot achieve.
The important qualification is that the human TSH dose-response curve for oral 3,5-T2 has not been formally characterized in rigorous controlled clinical trials. The 300 mcg/day threshold figure is extrapolated from the animal-model potency data and community tracking, not from a human pharmacodynamic study. Researchers using T2 at the higher end of the Scorch Protocol range should treat TSH monitoring as a standard research endpoint, consistent with the general principle that any thyroid-active compound warrants HPT-axis tracking.
How It Compares to Other T2 Protocols
The Scorch Protocol is not the only T2 research framework in circulation. Understanding its positioning requires contrasting it against the other approaches the research community uses.
Bioenergetic-school T2 use (anti-stress framing, paired with T3). The bioenergetic research tradition - associated with researchers like Georgi Dinkov and the Ray Peat-influenced metabolic research community - approaches T2 as part of a broader anti-stress bioenergetics framework. In this school, T2 is rarely used as a monotherapy tool; it appears as a component of broader metabolic optimization that includes T3, thyroid support, and anti-inflammatory nutritional protocols. The framing is less about fat-loss and lipid metabolism specifically and more about overall mitochondrial sufficiency and stress-hormone reduction. T2 in the bioenergetic school is paired with T3 rather than positioned as a standalone metabolic accelerator.
Wilson's T3+T2 enhanced protocol. The Wilson's T3+T2 enhanced protocol is the most structured combined-approach framework in the T3+T2 space. It extends the Wilson's cyclic T3 titration framework by adding T2 at a 1:1 mcg ratio with T3 at every step. The orientation is different from the Scorch Protocol: where Scorch is positioned as a metabolic-rate and lipid-metabolism tool with T2 as the primary active agent, the Wilson's T3+T2 approach is positioned as a correction for deiodinase dysfunction in hypothyroid-adjacent chronic illness populations. T3 carries the primary signal in the Wilson's framework; T2 is the mitochondrial co-activator that addresses the T3-to-T2 conversion failure that T3 supplementation alone cannot fix. The two protocols serve related but distinct research populations.
100 mcg fitness-supplement use. The fitness-supplement market has used T2 at fixed 100 mcg doses as a component of fat-burner formulations for more than a decade. This is the most widespread consumer exposure to T2, but it differs from the Scorch Protocol framework in several ways: the fitness-supplement use is typically continuous rather than cycled, is frequently combined with stimulant-class compounds in proprietary blends, and often lacks isomer specificity (product labels frequently say "T2" without specifying 3,5-diiodothyronine). The Scorch Protocol community explicitly distinguishes its framework from this category, emphasizing T2-monotherapy at research-grade specification and defined dosing rather than as a minor component of a stimulant-heavy blend.
What makes the Scorch Protocol distinct is its focus on T2-monotherapy as the primary research tool, centered on the lipid-metabolism and non-stimulant metabolic-acceleration framing, with dosing that is higher and more precisely defined than the typical fitness-supplement 100 mcg fixed dose. It occupies a specific niche: researchers who want to work with T2 directly, at doses anchored to the cytochrome c oxidase and hepatic fatty acid oxidation literature, without the T3 co-administration that the Wilson's framework requires.
The Conversion-Bottleneck Overlap
Even researchers working within the Scorch Protocol's T2-monotherapy framework benefit from understanding the T3-to-T2 conversion bottleneck - because the conversion problem can affect the research question being asked.
The T3→T2 conversion problem, analyzed in depth in the T3-to-T2 conversion problem and deiodinase dysfunction guide, describes the situation where the deiodinase enzymes responsible for converting T3 to 3,5-T2 are impaired by the same selenium deficiency, inflammatory cytokine load, and DIO1 dysfunction that creates T4-to-T3 conversion problems. A researcher or research subject in this population is not just T3-deficient relative to their T4 supply - they are T2-deficient relative to their T3 supply, because the enzymatic machinery to complete the downstream conversion is itself impaired.
For Scorch Protocol research, the conversion-bottleneck context changes the interpretation of outcomes. If a research subject runs a T2-monotherapy protocol and shows robust response - the metabolic rate elevation, lipid-metabolism effects, and temperature changes consistent with T2 activity - this could reflect both the direct cytochrome c oxidase pathway and the partial correction of a pre-existing T2 deficiency from impaired conversion. The same subjects who respond most strongly to Scorch Protocol T2 dosing may be those in whom endogenous T2 production was most severely impaired upstream.
More importantly, some research subjects who initially approach the Scorch Protocol framework - drawn by the lipid-metabolism and non-stimulant positioning - may find that their metabolic profile reflects impaired T4-to-T3 conversion as an upstream problem, not just the T3-to-T2 step. In these subjects, T2-monotherapy addresses the mitochondrial layer directly but leaves the genomic thyroid signaling layer - T3's domain - unsupported. The conversion-bottleneck analysis in the T3-to-T2 conversion guide addresses exactly this question: when does T2 alone provide sufficient research signal, and when does the population profile suggest a combined T3+T2 approach would be more complete?
Researchers who find T2-monotherapy insufficient for their research goals - or who are working with populations characterized by deiodinase dysfunction across both conversion steps - may find the Wilson's T3+T2 enhanced protocol more appropriate than the Scorch Protocol framework. The SRT3+T2-15 entry-strength capsule provides both T3 and T2 at the Step 2 titration level, representing the entry point for researchers transitioning from a T2-monotherapy Scorch approach toward a combined-protocol investigation.
What Research Has Established vs Hasn't
A rigorous breakdown of the Scorch Protocol requires separating what the peer-reviewed literature supports from what the research community has assembled as protocol architecture without clinical-trial validation.
Established:
3,5-T2 binds directly to cytochrome c oxidase subunit Va and acutely stimulates mitochondrial electron transport chain activity - this is established in multiple peer-reviewed studies beginning with the 1994 Goglia et al. FEBS Letters paper (PMID 8194599) and supported by subsequent replications. T2 administration in animal models accelerates fatty acid oxidation in hepatic mitochondria and elevates resting metabolic rate - this is documented in the Lanni et al. 2009 and related publications (PMID 19324040, PMID 22387024). 3,5-T2 has approximately 10 times lower TSH suppression potency than T3 in rodent models, reflecting its substantially weaker TRbeta affinity - confirmed by Rivas et al. and the comparative thyromimetic potency data (PMID 19033545, PMID 16219922). The muscle-sparing profile relative to T3 in equivalent metabolic-effect comparisons is supported by the rodent-model literature.
Hypothesis / research community:
The Scorch Protocol as a defined research regimen - with its specific dose ranges, cycling structure, and outcome framing - is a research-community-developed framework, not a validated clinical protocol. No published randomized controlled trial has tested the Scorch Protocol as described. The dose ranges, cycling schedules, and metabolic outcome claims circulating in research forums are assembled from the biochemistry and animal-model literature applied to a human-research context without the controlled-trial validation that would formally establish the protocol. The "lipid-cleansing" framing is community language that extends beyond what the peer-reviewed literature explicitly claims for human subjects.
Limitations:
Human clinical data on T2-monotherapy for fat-loss or lipid-metabolism outcomes are limited. The mechanistic studies are predominantly animal-model research - rodent hepatic mitochondria, ex vivo enzyme studies, whole-animal indirect calorimetry. The translational path from rodent liver mitochondria to human metabolic research subjects is real but involves assumptions that are not fully validated by human clinical trials. The handful of human studies examining T2 have focused primarily on TSH safety, serum half-life, and pharmacokinetic characterization rather than on the fat-loss and lipid-metabolism outcomes that Scorch Protocol framing emphasizes. Researchers should treat the rodent-to-human extrapolation with appropriate caution and design protocols that include measurable endpoints capable of detecting whether the expected effects are actually occurring in their specific research context.
Frequently Asked Questions
What is the Scorch Protocol?
The Scorch Protocol is a T2-focused metabolic research framework centered on the use of 3,5-diiodothyronine (3,5-T2) as a non-stimulant metabolic accelerator. The protocol is built on T2's direct mitochondrial mechanism - its binding to cytochrome c oxidase and acceleration of hepatic fatty acid oxidation - and is positioned specifically around lipid-metabolism outcomes and the TSH safety argument that T2 produces metabolic acceleration without the HPT-axis suppression that T3 protocols carry. The framework is described on scorchprotocol.com and discussed widely in metabolic-research forums. It is a community-developed research protocol, not a clinically validated regimen.
What dose of T2 does the Scorch Protocol use?
Research-forum discussions of the Scorch Protocol report three general ranges: a starting phase at 50-100 mcg/day (once daily, morning), a standard phase at 100-200 mcg/day (1-2 doses), and a higher-range research phase at 200-300 mcg/day (2-3 split doses). The community generally treats 300 mcg/day as the upper boundary where TSH suppression risk begins to enter the picture based on animal-model extrapolation. These dose figures are reported from research-community forum discussion and are not clinically validated dosing guidelines.
Does the Scorch Protocol suppress TSH?
At the typical Scorch Protocol dose range (100-300 mcg/day), T2 is not expected to produce meaningful TSH suppression based on the animal-model evidence. 3,5-T2 has approximately 10 times lower potency than T3 for TSH suppression, reflecting its much weaker affinity for TRbeta (the pituitary receptor that mediates negative feedback on TSH secretion). Consumer tracking and research-forum reporting consistently suggest that oral T2 below approximately 300 mcg/day does not produce primary TSH suppression as a consistent finding - though this has not been confirmed in controlled human pharmacodynamic studies. TSH monitoring is appropriate as a standard research safety endpoint for any thyroid-active compound.
How is the Scorch Protocol different from a fat-burner supplement?
The Scorch Protocol differs from mainstream fat-burner supplements in three ways. First, the mechanism is non-stimulant: T2 acts through the mitochondrial cytochrome c oxidase pathway rather than through CNS adrenergic stimulation. Second, the Scorch Protocol is T2-monotherapy at defined doses using research-grade 3,5-diiodothyronine, rather than T2 as one minor ingredient in a proprietary blend with stimulant-class compounds. Third, the Scorch Protocol framework emphasizes specific lipid-metabolism outcomes anchored to the peer-reviewed animal-model literature, rather than the broad thermogenic and energy claims common in supplement marketing. Researchers in the Scorch community typically specify 3,5-diiodothyronine by isomer identity and seek documented purity, neither of which is consistently available in the fitness-supplement fat-burner category.
Can T2 be combined with T3 (T3+T2)?
Yes - and the combined approach is well-supported mechanistically. T3 drives nuclear thyroid hormone receptor activation and the genomic metabolic cascade; T2 drives direct mitochondrial cytochrome c oxidase activation. The two mechanisms are complementary and non-overlapping: T3 cannot replicate T2's acute mitochondrial pathway, and T2 cannot replicate T3's genomic signaling. In research subjects with impaired DIO1 function, the second-step deiodinase conversion bottleneck means that T3 alone cannot sustain adequate T2 levels, making direct T2 co-supplementation the more complete approach. The specific combined approach structured around the Wilson's cyclic titration framework is described in the Wilson's T3+T2 enhanced protocol. The Wilson's T3+T2 Combo implements this combination at a 1:1 T3:T2 ratio in sustained-release capsules. The Scorch Protocol focuses on T2 monotherapy; the Wilson's T3+T2 approach addresses both the genomic and mitochondrial layers simultaneously.
Is the Scorch Protocol safe for thyroid-disease patients?
This is a question that falls outside the scope of research-community protocol discussion and into clinical medical advice - which this article does not provide. Individuals with existing thyroid conditions are managing a complex hormonal system under the supervision (or without the supervision) of a clinical endocrinologist, and the introduction of any exogenous thyroid-active compound into that picture carries clinical implications that require individual medical evaluation. All compounds discussed here are sold for research purposes only and are not for human consumption. The TSH safety argument in the Scorch Protocol applies to research subjects without pre-existing thyroid pathology being tracked for that specific endpoint - it does not constitute a safety assurance for individuals with diagnosed thyroid disease.
How long does it take to see results?
The time course for T2 research outcomes has two components, consistent with the dual nature of T2's mechanism. The acute cytochrome c oxidase activation - elevated cellular respiration, accelerated fatty acid oxidation - is theoretically rapid, measurable in animal models within minutes to hours of administration. Research-forum accounts of the Scorch Protocol generally describe noticing thermogenic changes, body-temperature shifts, and energy-level changes within the first several days of initiating the protocol at the standard dose range. The longer-horizon component - body composition changes, sustained lipid-profile shifts, cumulative metabolic rate normalization - is reported in the research community as unfolding over weeks of consistent dosing within a defined cycle. The two-component response (rapid initial signal, gradual sustained outcome) is consistent with T2's mechanism: immediate cytochrome c oxidase stimulation on a timescale of hours, longer-range metabolic consequences accumulating over weeks.
Where do I get research-grade T2?
Research-grade 3,5-T2 requires a supplier that specifies 3,5-diiodo-L-thyronine (not generic "T2"), provides HPLC-verified assay documentation or Certificate of Analysis, and discloses the excipient profile of the finished formulation. Generic "T2" labels that do not identify the isomer cannot confirm whether the product contains the metabolically active 3,5- isomer rather than the inactive 3,3'-T2 isomer - a distinction that is decisive for research validity. For researchers working at the T2-plus-T3 level, the SRT3+T2-15 entry-strength capsule provides both components at research-grade specification. The full range of available T3, T2, and combination research compounds is listed in the catalog.
Closing Note
The Scorch Protocol represents the most visible T2-focused research framework in the metabolic-research community - a protocol built on the three claims that have consistently driven T2 interest: direct mitochondrial cytochrome c oxidase activation, hepatic fatty acid oxidation acceleration, and a TSH safety profile substantially more favorable than T3. The peer-reviewed animal-model literature supports all three underlying mechanisms. The specific protocol as a defined human-research regimen is community-developed, not clinically validated.
Where the Scorch Protocol's T2-monotherapy framing has limits - specifically for research subjects whose metabolic profile reflects both T3 and T2 deficiency from upstream deiodinase dysfunction - the combined T3+T2 approach is more appropriate. The Wilson's T3+T2 enhanced protocol and the Wilson's T3+T2 Combo address both the genomic and mitochondrial layers simultaneously, for research populations in whom T2 alone cannot complete the signaling picture. For researchers beginning at the entry level of T3+T2 combined research, the SRT3+T2-15 provides a starting point at the Step 2 titration dose. The full range of thyroid research compounds - T3, T2, and combination formulations - is available in the catalog.